Literature DB >> 10081633

Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders.

M A Nalesnik1, A Zeevi, P S Randhawa, A Faro, K J Spichty, A J Demetris, J J Fung, T L Whiteside, T E Starzl.   

Abstract

Cytokine mRNA patterns were analyzed in 11 post-transplant lymphoproliferative disorder (PTLD) specimens using qualitative reverse-transcriptase polymerase chain reaction (RT-PCR). In each case, a pattern of IL2-, IFN gamma-, IL4+, IL10+ was seen. A similar pattern was observed in a spleen sample from 1 patient with contemporaneous PTLD elsewhere. Semiquantitative RT-PCR for cytokine message was performed using RNA from bronchoalveolar lavage (BAL) specimens obtained from 2 patients with pulmonary PTLD. In both cases, IL4 message predominated. Reduction of message coincided with resolution of the tumors. The pattern differed from that seen in 1 patient with acute pulmonary rejection, in which RT-PCR of BAL cells showed predominance of IL6 and IFN gamma. We conclude that at least some PTLDs exist within a T-helper cell type 2 (Th2)-like cytokine microenvironment. The presence of a similar mRNA pattern in an extratumoral specimen at the time of PTLD suggests that it may reflect a systemic phenomenon. Disappearance of this pattern following PTLD resolution indicates its dynamic nature and is consistent with the hypothesis that specific cytokines contribute to the development of PTLDs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081633      PMCID: PMC3022484          DOI: 10.1034/j.1399-0012.1999.t01-2-130106.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  21 in total

Review 1.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  The rapid development of a fatal, disseminated B cell lymphoma following liver transplantation--serial changes in levels of soluble serum interleukin 2 and interleukin 4 (B cell growth factor).

Authors:  G W Burke; R Cirocco; G Hensley; R Reddy; L Jeffers; E Schiff; J Miller
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

3.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

4.  Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.

Authors:  H E Heslop; M K Brenner; C Rooney; R A Krance; W M Roberts; R Rochester; C A Smith; V Turner; J Sixbey; R Moen
Journal:  Hum Gene Ther       Date:  1994-03       Impact factor: 5.695

Review 5.  Epstein-Barr virus strategy in normal and neoplastic B cells.

Authors:  G Klein
Journal:  Cell       Date:  1994-06-17       Impact factor: 41.582

Review 6.  The potential role of cytokines in the pathogenesis of Epstein-Barr virus associated post-transplant lymphoproliferative disease.

Authors:  P S Randhawa; A J Demetris; M A Nalesnik
Journal:  Leuk Lymphoma       Date:  1994-11

7.  Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders.

Authors:  A Mathur; D M Kamat; A H Filipovich; M Steinbuch; R S Shapiro
Journal:  Transplantation       Date:  1994-04-15       Impact factor: 4.939

8.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.

Authors:  E B Papadopoulos; M Ladanyi; D Emanuel; S Mackinnon; F Boulad; M H Carabasi; H Castro-Malaspina; B H Childs; A P Gillio; T N Small
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

9.  Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy.

Authors:  D W Hanto; K J Gajl-Peczalska; G Frizzera; D C Arthur; H H Balfour; K McClain; R L Simmons; J S Najarian
Journal:  Ann Surg       Date:  1983-09       Impact factor: 12.969

10.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Authors:  C M Rooney; C A Smith; C Y Ng; S Loftin; C Li; R A Krance; M K Brenner; H E Heslop
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

View more
  4 in total

1.  Early tolerance in pediatric liver allograft recipients.

Authors:  A G Tzakis; J Reyes; A Zeevi; H Ramos; B Nour; N Reinsmoen; S Todo; T E Starzl
Journal:  J Pediatr Surg       Date:  1994-06       Impact factor: 2.545

Review 2.  Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.

Authors:  Gyula Végso; Melinda Hajdu; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2010-12-31       Impact factor: 3.201

Review 3.  Interferon-alpha and its effects on post-transplant lymphoproliferative disorders.

Authors:  A Faro
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.